CA3140137A1 - Eltrombopag dosing regimen - Google Patents
Eltrombopag dosing regimen Download PDFInfo
- Publication number
- CA3140137A1 CA3140137A1 CA3140137A CA3140137A CA3140137A1 CA 3140137 A1 CA3140137 A1 CA 3140137A1 CA 3140137 A CA3140137 A CA 3140137A CA 3140137 A CA3140137 A CA 3140137A CA 3140137 A1 CA3140137 A1 CA 3140137A1
- Authority
- CA
- Canada
- Prior art keywords
- eltrombopag
- tapering
- dose
- treatment
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/032171 WO2020231407A1 (en) | 2019-05-14 | 2019-05-14 | Eltrombopag dosing regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3140137A1 true CA3140137A1 (en) | 2020-11-19 |
Family
ID=67211802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3140137A Pending CA3140137A1 (en) | 2019-05-14 | 2019-05-14 | Eltrombopag dosing regimen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220313663A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3968984A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022537883A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220035036A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019445762A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3140137A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288078A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021013971A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020231407A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201406373A (zh) * | 2012-06-29 | 2014-02-16 | Shionogi & Co | 含有具有血栓形成素受體促效作用之化合物之醫藥組合物 |
-
2019
- 2019-05-14 EP EP19737274.1A patent/EP3968984A1/en not_active Withdrawn
- 2019-05-14 CA CA3140137A patent/CA3140137A1/en active Pending
- 2019-05-14 JP JP2021568408A patent/JP2022537883A/ja not_active Withdrawn
- 2019-05-14 MX MX2021013971A patent/MX2021013971A/es unknown
- 2019-05-14 IL IL288078A patent/IL288078A/en unknown
- 2019-05-14 WO PCT/US2019/032171 patent/WO2020231407A1/en not_active Ceased
- 2019-05-14 AU AU2019445762A patent/AU2019445762A1/en not_active Abandoned
- 2019-05-14 KR KR1020217040929A patent/KR20220035036A/ko not_active Ceased
- 2019-05-14 US US17/611,012 patent/US20220313663A1/en not_active Abandoned
-
2023
- 2023-09-27 JP JP2023166306A patent/JP2023182667A/ja active Pending
- 2023-11-27 AU AU2023274065A patent/AU2023274065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023182667A (ja) | 2023-12-26 |
| AU2019445762A1 (en) | 2021-12-09 |
| MX2021013971A (es) | 2022-04-01 |
| AU2023274065A1 (en) | 2023-12-14 |
| JP2022537883A (ja) | 2022-08-31 |
| US20220313663A1 (en) | 2022-10-06 |
| IL288078A (en) | 2025-01-01 |
| WO2020231407A1 (en) | 2020-11-19 |
| KR20220035036A (ko) | 2022-03-21 |
| EP3968984A1 (en) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6746495B2 (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP7295305B2 (ja) | ループス腎炎の治療のための改善されたプロトコル | |
| TWI729022B (zh) | 用於治療葡萄膜炎及黃斑水腫之包含il6r抗體的組合物與其使用方法 | |
| JP2024530954A5 (cg-RX-API-DMAC7.html) | ||
| Desideri et al. | Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage | |
| US20170224815A1 (en) | Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition | |
| JP2016516761A5 (cg-RX-API-DMAC7.html) | ||
| US9920131B2 (en) | Dosage and administration of anti-EGFR therapeutics | |
| JP2021152002A5 (cg-RX-API-DMAC7.html) | ||
| WO2020231408A1 (en) | Eltrombopag dosing regimen | |
| AU2023274065A1 (en) | Eltrombopag dosing regimen | |
| CN107249586A (zh) | 用于治疗精神分裂症的伊潘立酮 | |
| US20230167189A1 (en) | Treatment of Multiple Sclerosis with Anti-CD52 Antibodies | |
| JP2024516886A5 (cg-RX-API-DMAC7.html) | ||
| McNeil | Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity | |
| JP2020172471A (ja) | ヒト化抗ヒトcd26抗体を含有する医薬組成物 | |
| Shah et al. | Clinical Trials in Age-related Macular Degeneration-IV | |
| Delaney et al. | Emerging treatments for non-infectious uveitis | |
| Dalton et al. | Ranibizumab achieves higher BCVA gains for BRVO in COMRADE-B. | |
| Narayanan et al. | Corticosteroids: Triamcinolone, Dexamethasone | |
| TH2001001181A (th) | วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf | |
| Bilgec et al. | Intravitreal Dexamethasone Implant (Ozurdex) for Macular Edema Secondary to Retinal Vein Occlusion | |
| WO2019231800A1 (en) | Anti-cgrp antibodies for treating menstrual-related migraines | |
| Gillies | CLINICAL EFFICACY SAFETY PHARMACOLOGY PHARMACOKINETICS ROUTE OF ADMINISTRATION | |
| INGERMAN et al. | Emerging Treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240403 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250610 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260625 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |